Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

Carna announces an upcoming poster presentation at AACR Annual Meeting

Carna Announces to Extend the Agreement with Sumitomo Pharma on Joint Research, Development, and Commercialization of Kinase Inhibitors

Corporate Presentation Feb. 2025

FY2024 Presentation

Consolidated Financial Results for the Year Ended December 31, 2024

Carna’s collaborator Wins ASH Abstract Achievement Award

Carna announces a poster presentation on preliminary results from ongoing Phase 1b study for its non-covalent BTK inhibitor docirbrutinib (AS-1763) at American Society of Hematology Annual Meeting

Carna announces a poster presentation featuring preclinical findings of its non-covalent BTK inhibitor docirbrutinib (AS-1763) at American Society of Hematology Annual Meeting